Royce & Associates LP lifted its holdings in shares of Artivion, Inc. (NYSE:AORT – Free Report) by 39.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 889,702 shares of the company’s stock after purchasing an additional 250,420 shares during the quarter. Royce & Associates LP’s holdings in Artivion were worth $20,303,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the business. BlackRock Inc. bought a new position in shares of Artivion during the 2nd quarter valued at about $149,965,000. Bank of America Corp DE bought a new stake in Artivion during the 2nd quarter worth approximately $11,717,000. Aberdeen Group plc bought a new stake in Artivion during the 3rd quarter worth approximately $11,891,000. Legal & General Group Plc acquired a new stake in Artivion during the 2nd quarter worth approximately $5,826,000. Finally, Bank of New York Mellon Corp acquired a new stake in Artivion during the 2nd quarter worth approximately $5,671,000. Institutional investors own 86.37% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. Canaccord Genuity Group cut their price target on shares of Artivion from $40.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, November 6th. Wall Street Zen downgraded shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Needham & Company LLC restated a “buy” rating and set a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Artivion in a report on Wednesday, November 4th. Finally, Jefferies Financial Group started coverage on shares of Artivion in a research report on Tuesday, October 20th. They issued a “buy” rating and a $31.00 price objective on the stock. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $39.00.
Check Out Our Latest Stock Analysis on AORT
Insider Activity
In related news, CEO James P. Mackin sold 70,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Andrew M. Green sold 11,480 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $24.97, for a total value of $286,655.60. Following the sale, the senior vice president owned 40,160 shares in the company, valued at $1,002,795.20. The trade was a 22.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 89,483 shares of company stock valued at $2,529,531 in the last 90 days. 6.30% of the stock is owned by corporate insiders.
Artivion Price Performance
Shares of AORT opened at $19.11 on Monday. The stock has a market capitalization of $932.47 million, a P/E ratio of -53.09 and a beta of 1.31. Artivion, Inc. has a twelve month low of $18.95 and a twelve month high of $48.25. The company has a 50 day moving average of $22.89 and a 200-day moving average of $28.40. The company has a quick ratio of 3.02, a current ratio of 4.42 and a debt-to-equity ratio of 0.82.
Artivion (NYSE:AORT – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.14. Artivion had a negative net margin of 3.65% and a positive return on equity of 5.12%. The firm had revenue of $123.79 million for the quarter, compared to analyst estimates of $120.97 million.
Artivion Profile
Artivion, Inc. is a medical device company focused on treating aortic disease and supporting cardiac and vascular surgery. Its products include aortic stent grafts and surgical grafts, mechanical heart valves, and BioGlue, a surgical adhesive used in cardiovascular procedures. The company was founded as CryoLife and adopted the Artivion name in 2022. It serves healthcare providers in the United States and international markets. Artivion is headquartered in Kennesaw, Georgia. Its chief executive officer is Pat Mackin.
Featured Articles
- Five stocks we like better than Artivion
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding AORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Artivion, Inc. (NYSE:AORT – Free Report).
Receive News & Ratings for Artivion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artivion and related companies with MarketBeat.com's FREE daily email newsletter.
